Estimation of ascertainment bias and its effect on power in clinical trials with time-to-event outcomes

E. J. Greene, P. Peduzzi, J. Dziura +4

While the gold standard for clinical trials is to blind all parties -- participants, researchers, and evaluators -- to treatment assignment, this is not always a possibility. When…